Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose CAM2043 in Raynaud's phenomenon secondary to systemic sclerosis
2019-002444-24Phase 2Unknown
- Sponsor
- Camurus
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of CAM2043 in Raynaud disease, sponsored by Camurus. Primary endpoint: Change from baseline to 6 hours post-dose in AUC for reperfusion/rewarming. Status: unknown.
02
Drugs
CAM2043
03
Conditions
Raynaud disease
Beyond the preview
Go deeper on 2019-002444-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002444-24.